Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of ranibizumab in choroidal neovascularization secondary to pathological myopia
2009-014854-14Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2009
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ranibizumab in Choroidal Neovascularization (CNV) and Subretinal neovascularization, sponsored by Novartis. Primary endpoint: Change in best corrected visual acuity (BCVA) from baseline to month 12. Started Oct 2009; status: completed.
02
Drugs
ranibizumab
03
Conditions
Choroidal Neovascularization (CNV)Subretinal neovascularization
Beyond the preview
Go deeper on 2009-014854-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014854-14.